Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H7N3O |
Molecular Weight | 137.1393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NNC(=O)C1=CC=NC=C1
InChI
InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
Molecular Formula | C6H7N3O |
Molecular Weight | 137.1393 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00951
http://www.rxlist.com/isoniazid-drug.htm
Curator's Comment: Description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00951
http://www.rxlist.com/isoniazid-drug.htm
Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. Isoniazid is a prodrug and must be activated by bacterial catalase. Isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. The most frequent adverse reactions to isoniazid are those affecting the nervous system and the liver.
CNS Activity
Sources: http://www.bmj.com/content/341/bmj.c4451
Curator's Comment: Isoniazid easily crosses the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1849 Sources: http://www.drugbank.ca/drugs/DB00951 |
0.75 nM [Ki] | ||
Target ID: P9WIE4|||Q50553 Gene ID: NA Gene Symbol: katG Target Organism: Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh) Sources: http://www.drugbank.ca/drugs/DB00951 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Isoniazid Approved Useall forms of tuberculos in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Also is recommended as preventive therapy Launch Date2.73024E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg 2 times / week multiple, oral dose: 15 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 μg/kg bw 1 times / day multiple, oral dose: 5 μg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.6 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.81 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
53.17 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg 2 times / week multiple, oral dose: 15 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6.96 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
9.71 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 μg/kg bw 1 times / day multiple, oral dose: 5 μg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
71.52 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.06 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/ |
5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
86% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29735566/ |
unknown, unknown |
ISONIAZID plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Sources: Page: p.294Vomiting Grand mal seizure Lethargy Coma |
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.295 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.295 |
Disc. AE: Nystagmus, Hyperreflexia... AEs leading to discontinuation/dose reduction: Nystagmus Sources: Page: p.295Hyperreflexia |
112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: |
Disc. AE: Lethargy, Seizures... AEs leading to discontinuation/dose reduction: Lethargy Sources: Seizures Coma Tachycardia |
25 g single, oral Overdose Dose: 25 g Route: oral Route: single Dose: 25 g Co-administed with:: pyridoxine, p.o(2.5 mg, single) Sources: Page: p.2 |
healthy, 20 n = 1 Health Status: healthy Age Group: 20 Sex: F Population Size: 1 Sources: Page: p.2 |
Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure Sources: Page: p.2 |
900 mg 1 times / week multiple, oral Recommended Dose: 900 mg, 1 times / week Route: oral Route: multiple Dose: 900 mg, 1 times / week Co-administed with:: rifapentine, p.o(900 mg; 1/week) Sources: Page: p.2160 |
unhealthy, 25–47 n = 3986 Health Status: unhealthy Condition: Tuberculosis Age Group: 25–47 Sex: M+F Population Size: 3986 Sources: Page: p.2160 |
Disc. AE: Hepatotoxicity, Hypersensitivity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (0.3%) Sources: Page: p.2160Hypersensitivity (2.9%) |
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: 73/127 |
healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: Page: 73/127 |
Disc. AE: Seizures, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Seizures (severe) Sources: Page: 73/127Metabolic acidosis Coma Oliguria |
900 mg 3 times / week multiple, oral Recommended Dose: 900 mg, 3 times / week Route: oral Route: multiple Dose: 900 mg, 3 times / week Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Tuberculosis Sources: Page: p.1 |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (grade 5) Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Grand mal seizure | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Lethargy | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Nausea | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Vomiting | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.294 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.294 |
Hyperreflexia | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.295 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.295 |
Nystagmus | Disc. AE | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: Page: p.295 |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: Page: p.295 |
Coma | Disc. AE | 112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: |
Lethargy | Disc. AE | 112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: |
Seizures | Disc. AE | 112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: |
Tachycardia | Disc. AE | 112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: |
Generalized tonic-clonic seizure | Disc. AE | 25 g single, oral Overdose Dose: 25 g Route: oral Route: single Dose: 25 g Co-administed with:: pyridoxine, p.o(2.5 mg, single) Sources: Page: p.2 |
healthy, 20 n = 1 Health Status: healthy Age Group: 20 Sex: F Population Size: 1 Sources: Page: p.2 |
Hepatotoxicity | 0.3% Disc. AE |
900 mg 1 times / week multiple, oral Recommended Dose: 900 mg, 1 times / week Route: oral Route: multiple Dose: 900 mg, 1 times / week Co-administed with:: rifapentine, p.o(900 mg; 1/week) Sources: Page: p.2160 |
unhealthy, 25–47 n = 3986 Health Status: unhealthy Condition: Tuberculosis Age Group: 25–47 Sex: M+F Population Size: 3986 Sources: Page: p.2160 |
Hypersensitivity | 2.9% Disc. AE |
900 mg 1 times / week multiple, oral Recommended Dose: 900 mg, 1 times / week Route: oral Route: multiple Dose: 900 mg, 1 times / week Co-administed with:: rifapentine, p.o(900 mg; 1/week) Sources: Page: p.2160 |
unhealthy, 25–47 n = 3986 Health Status: unhealthy Condition: Tuberculosis Age Group: 25–47 Sex: M+F Population Size: 3986 Sources: Page: p.2160 |
Coma | Disc. AE | 3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: 73/127 |
healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: Page: 73/127 |
Metabolic acidosis | Disc. AE | 3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: 73/127 |
healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: Page: 73/127 |
Oliguria | Disc. AE | 3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: 73/127 |
healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: Page: 73/127 |
Seizures | severe Disc. AE |
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: 73/127 |
healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: Page: 73/127 |
Hepatitis | grade 5 Disc. AE |
900 mg 3 times / week multiple, oral Recommended Dose: 900 mg, 3 times / week Route: oral Route: multiple Dose: 900 mg, 3 times / week Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Tuberculosis Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Ki 102 uM] | ||||
yes [Ki 110 uM] | ||||
yes [Ki 126 uM] | ||||
yes [Ki 13 uM] | ||||
yes [Ki 51.8 uM] | ||||
yes [Ki 60 uM] | ||||
yes [Ki >1000 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/8354023/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. | 1999 Dec |
|
Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives. | 1999 Nov-Dec |
|
Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients. | 1999 Sep |
|
A new class of antituberculosis agents. | 2000 Aug 24 |
|
Acute isoniazid neurotoxicity during preventive therapy. | 2000 Feb |
|
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. | 2000 Jul 4 |
|
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. | 2000 Jun |
|
Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. | 2000 Nov |
|
The role of fluoroquinolones in tuberculosis today. | 2001 |
|
Effect of preoperative chemotherapy on the outcome of surgical treatment of vertebral tuberculosis: retrospective analysis of 434 cases. | 2001 |
|
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell. | 2001 Apr |
|
Higher activity of morphazinamide over pyrazinamide against intracellular. | 2001 Apr |
|
Utility of PCR assays for rapid diagnosis of BCG infection in children. | 2001 Apr |
|
Heteroresistance in Mycobacterium tuberculosis. | 2001 Apr |
|
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. | 2001 Apr |
|
A clinic-based molecular epidemiologic study of tuberculosis in Monterrey, Mexico. | 2001 Apr |
|
A whole blood bactericidal assay for tuberculosis. | 2001 Apr 15 |
|
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. | 2001 Apr 20 |
|
Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids. | 2001 Apr 25 |
|
[Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS]. | 2001 Feb |
|
[Bronchiolo-alveolar cell carcinoma arising after active pulmonary tuberculosis' report of two cases]. | 2001 Feb |
|
TB prevention in HIV clinics in New York City. | 2001 Feb |
|
Facial granulomatous diseases: a study of four cases tested for the presence of Mycobacterium tuberculosis DNA using nested polymerase chain reaction. | 2001 Feb |
|
Incentives vs outreach workers for latent tuberculosis treatment in drug users. | 2001 Feb |
|
Antimycobacterial in vitro activity of cobalt(II) isonicotinoylhydrazone complexes. Part 10. | 2001 Feb 12 |
|
Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. | 2001 Jan |
|
Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population? | 2001 Jan |
|
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?]. | 2001 Jan |
|
Comparison of two rapid colorimetric methods for determining resistance of mycobacterium tuberculosis to rifampin, isoniazid, and streptomycin in liquid medium. | 2001 Jan |
|
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? | 2001 Jan |
|
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. | 2001 Jan |
|
[Two children with extrapulmonary symptoms due to tuberculosis]. | 2001 Jan 20 |
|
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. | 2001 Jan 26 |
|
Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. | 2001 Mar |
|
Survey for tuberculosis in a tribal population in North Arcot District. | 2001 Mar |
|
[Central nervous system tuberculosis in children: 2. Treatment and outcome]. | 2001 Mar |
|
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. | 2001 Mar |
|
Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. | 2001 Mar |
|
First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. | 2001 Mar |
|
The uses of error: iatrogenic hepatitis. | 2001 Mar 10 |
|
[Resistant tuberculosis in Denmark]. | 2001 Mar 26 |
|
Efficacy of chemotherapy for prostatic tuberculosis-a clinical and histologic follow-up study. | 2001 May |
|
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia. | 2001 May |
|
Substandard tuberculosis drugs on the global market and their simple detection. | 2001 May |
|
Influence of endothelium in dose-dependent inhibition and potentiation by isoniazid of isosorbide dinitrate relaxation of rat aorta. | 2001 May |
|
Isoniazid-induced beta-hydroxybutyric acidosis. | 2001 May 1 |
|
Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2. | 2001 May 10 |
Patents
Sample Use Guides
Adults: 5 mg/kg up to 300 mg daily in a single dose; or 15 mg/kg up to 900 mg/day, two or three times/week
Children: 10 mg/kg to15 mg/kg up to 300 mg daily in a single dose; or 20 mg/kg to 40 mg/kg up to 900 mg/day, two or three times/week
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10582897
Curator's Comment: MIC90 (minimum inhibitory concentration at which 90% of the test strains were inhibited) of isoniazid for Mycobacterium tuberculosis is 1.56 μg/ml.
1.56 μg/ml
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:17:20 UTC 2022
by
admin
on
Fri Dec 16 16:17:20 UTC 2022
|
Record UNII |
V83O1VOZ8L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175483
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ETH/ISO)
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM01
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AC01
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AC51
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM04
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM06
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM01
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM05
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
NCI_THESAURUS |
C280
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM03
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ETH/ISO/PYR/RIF)
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ETH/ISO/RIF)
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM02
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM04
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
LIVERTOX |
NBK548754
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM03
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
FDA ORPHAN DRUG |
6585
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM08
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AC01
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM05
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM02
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ISO/RIF)
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-VATC |
QJ04AM06
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4 (ISO/PYR/RIF)
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AC51
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
||
|
WHO-ATC |
J04AM07
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1647
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
V83O1VOZ8L
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
1497
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
6038
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | RxNorm | ||
|
9659
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
M6502
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | Merck Index | ||
|
SUB08326MIG
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
Isoniazid
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
CHEMBL64
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
4188
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
54-85-3
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
200-214-6
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
V83O1VOZ8L
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
6030
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
1349706
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
D007538
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
3767
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
DB00951
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
DTXSID8020755
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
ISONIAZID
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in 8 parts of water and in 40 parts of ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Tuberculostatic. Storage: Isoniazid should be kept in a well-closed container, protected from light. Definition: Isoniazid contains not less than 98.0% and not more than 101.0% of C6H7N3O, calculated with reference to the dried substance. | ||
|
C600
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY | |||
|
ISONIAZID
Created by
admin on Fri Dec 16 16:17:20 UTC 2022 , Edited by admin on Fri Dec 16 16:17:20 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
MIC value of the in vitro growth of Mycobacterium Tuberculosis (H37RV strain) of the new anti-tuberculosis terpenoid derived agent tested was 0.02?0.04 ug/ml.
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE TOXIC -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |